Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Twenty U.S. states including California, Connecticut and Michigan have pushed back against a $10 million settlement that Florida reached with Swiss generic drugmaker Sandoz, saying a key provision ...

However, the World Health Organization (WHO) warns of a global threat called antimicrobial resistance (AMR). (1) Bac ...

Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...

Ozempic currently costs about $218 per month in Canada, but once generic drugs are on the scene, the price is expected to be ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Novartis spun off ophthalmology subsidiary Alcon in 2019 and generic drug subsidiary Sandoz in 2023, and announced plans to focus on advanced original drugs in areas like oncology.

The U.S. over the counter (OTC) drugs market was valued at US$ 41.93 billion in 2024 and is projected to reach a market valuation of US$ 69.65 billion by 2033, growing at a CAGR of 5.8% during the ...